Drug Profile
Allogeneic human adipose-derived mesenchymal stem cell therapy - AbelZeta Pharma
Alternative Names: Allogenic Adipose tissue-derived mesenchymal progentior cells; Allogenic haMPC therapy - AbelZeta Pharma; AlloJoin; Mesenchymal progenitor cellsLatest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Cellular Biomedicine Group
- Developer AbelZeta Pharma
- Class Antirheumatics; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
- 18 Aug 2023 Cellular Biomedicine Group plans a phase III trial for Osteoarthritis (In adults, In the elderly) in China (Intra-articular, Injection) (NCT05996224)
- 31 Jul 2023 Cellular Biomedicine completes a phase II trial for Osteoarthritis (In adults, In the elderly) in China (Intra-articular) (NCT04208646)